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Summary Transitional cell carcinomas may arise at any site within the unnary tract and are a source of considerable morbidity and mortality.
In particular. patients with metastatic disease have a poor prognosis. with less than 50O alive at 5 years. A multicentre randomized trial
comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced or metastatic transitional cell
carcinoma was conducted in the UK. From April 1991 to June 1995. 214 patients were entered by 16 centres, 108 randomized to CMV and
106 to MV. A total of 204 patients have died. The hazard ratio (relative risk of dying) was 0.68 (950o Cl 0.51-0.90. P-value = 0.0065) in favour
of CMV. This translates to an absolute improvement in 1-year survival of 13%, 16% in MV and 29% in CMV. The median survival for CMV and
MV was 7 months and 4.5 months respectively. Two hundred and eight patients objectively progressed or died. The hazard ratio was 0.55
(95% Cl 0.41-0.73, P-value = 0.0001) in favour of CMV. Two hundred and nine patients symptomatically progressed or died. The hazard ratio
was 0.48 (950°o Cl 0.36-0.64. P-value = 0.0001) in favour of CMV. The most important pretreatment factors influencing overall survival were
WHO performance status and extent of disease. These two factors were used to derive a prognostic index which could be used to categorize
patients into three prognostic groups. We conclude that the addition of cisplatin to methotrexate and vinblastine should be considered in
patients with transitional cell carcinoma, taking into account the increased toxicity.
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Transitional cell carcinomas (TCCs) mav arise at anx site within the
unrnarx tract and are a source of considerable morbiditx and
mortalitv. In 1994. there A-ere 5300 deaths from this disease in the
UK (Cancer Research Campaign. 1995). Approximately 90% of
these cancers arise in the bladder. occumrng at a median ag,e of 65
Xears. Treatment ofpatient.s with disease confined to the bladder(1T2
or T3) w-ith radiotherapy or cystectomy results in cure in 30-40%7
of cases. Patients w-ith metastatic disease hax-e a much poorer
prognosis. with less than 5%- alix-e at 5 vears (Saxman et al. 1997).
During the last 15-20 years. chemotherapy. predominantly
using the drugs methotrexate. Xinblastine. cisplatin and doxo-
rubicin. has been w-idelx used to treat these cancers (Sternberg.
1995). Early randomized trials using combinations of these drugs.
usually compared w-ith cisplatin as a single-agent control. A-ere
able to demonstrate their moderate actix itv (Gaaliano et al. 1983:
Soloway et al. 1983: Khandekar et al. 1985: Troner et al. 1987:
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Hillcoat et al. 1989). Hox-exer. response and surxival were gener-
ally short and no clear benefit for combination chemotherapy
could be demonstrated. However. with the dexelopment of metho-
trexate -inblastine adriamvcin(doxorubicin) cisplatin (IM-VAC)
(Sternberg et al 1985. 1988. 1989). a drug combination incorpo-
rating all these drugs. and CMV (omittinc doxorubicin: Hark-er et
al. 1985: Jeffern et al. 1992). large improvements in remission rate
were reported in single-institution studies. with reports of long-
term sunrival in 20'c of patients in one study (Sternberg et al.
1989). In a subsequent randomized trial. howexer. comparing
single-agent cisplatin wxith M-VAC (Loehrer et al. 1992). the
essentially palliative nature of these treatments was demonstrated.
W'hile M-VAC proxed capable of increasing median sun-ixal time
from 8 months to 12 months. a 5-y ear progression-free surnival of
only 4%/c wxas reported (Saxman et al. 1997). Similarlx. in a large
retrospective study of patients receix ing cisplatin combination
chemotherapy for locally adx anced or metastatic urothelial cancer
Fossa et al. 19961. a 5-xear survival rate of only 11'k wxas
reported. M-VAC has also been reported to improxe surnixval wxhen
compared with CISCA (cisplatin. cyclophosphamide and doxoru-
bicin) in a randomized trial (Logothetis et al. 1990).
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Combination chemotherapy including, cisplatin is toxic.
resulting in marked morbidity- for the majority of patients and
treatment-related mortality in up to 4%,c of cases (Loehrer et al.
1992). Cisplatin itself is probably responsible for most of the
impairment of quality of life. and the precise role of this drug in
the management of these cancers has not been clearlv demon-
strated. Cisplatin-based treatment can also be inconvenient to the
patient. usually requirinc hospitalization for administration. In the
trial comparing single-agent cisplatin with M-VAC (Loehrer et al.
1992). an overall response rate of only 12%7c A-as described for
cisplatin used as a single agent.
In 1991. the British MIedical Research Council initiated a trial
comparing, combination chemotherapy with CMV (cisplatin gixen
at a dose of 70 mg, m-') with a modified methotrexate and Xinblas-
tine (MV) regrimen. This latter regimen can be gaixen on an out-
patient basis and was reported as providing a 40%7c response rate
(complete response plus partial response) in metastatic transitional
cell cancer when used on a weekly basis (Ahmed et al. 1985). This
trial was designed to ex aluate the impact ofcisplatin on this disease.
PATIENTS AND METHODS
Study design and randomization
Patients eligible for this study had to have a histologically
confirmed diarnosis of transitional cell carcinoma arising at any
site in the urothelial tracts. Patients with mixed tumours (i.e.
tumours containing elements of squamous cell or adenocarci-
noma) were also eligible for inclusion in this studv. although
patients '-ith pure non-TCC tumours w-ere excluded. Patients
should have been considered incurable by surgery or radiotherapy
and the follow-ing groups were included: (1) metastatic disease at
anv site (includinc completely resected pelvic nodal disease). (2)
invasive pelvic relapse after radical radiotherapy and (3) initial
presentation '-ith T4b disease. It Aas not considered essential that
patients had measurable disease. as the primary end point of the
study Aas length of sun-ival.
Further elicribilitv criteria wxere as follows: all patients were
required to have a nonnal blood count (WBC > 3.5 x l0 1-1 with
a platelet count > 100 x 109 1-1) and a glomerular filtration rate
(GFR). calculated bh the method ofCockcroft and Gault (1976) of
> 50 ml mmn-1. if necessarv achiexed by ureteric stenting or percu-
taneous drainage of the urinarv tract where obstruction Aas
present. All patients had to be considered fit to x ithstand treatment
'-ith cisplatin-containing chemotherapy. and no previous systemic
chemotherapy was permitted. Patients w-ith concomitant or
previous malignancy other than basal cell carcinoma of the skin or
CIS of the cerx ix Aere also excluded from study entrx. The
protocol was revie' ed in each institution bx the local ethics
committees. and informed consent to inclusion in the study was
given by all patients.
Elicribilitv of patients w-as confirmed and randomization
performed by a telephone call to the Medical Research Council
Cancer Trials Office. Randomization was by the method of mini-
mization with stratification factors of centre. performance status
and the presence or absence of visceral disease.
To help design this trial. members of the Advanced Bladder
Cancer Workintc Partv w'ere asked what. in their opinion. 'Aas the
improxement in 2-vear survixal they would wish to see before
changin, treatment from MV to CMV. The oxerall results indicated
that approximate clinical equivalence would be demonstrated if the
absolute benefit to CMV w-as less than 10-15%7c. To exclude an
absolute improvement larger than 15% (that is. say. from 20% in the
CMV arm to 5% or less in the MV arm) required that 200 patients
Awere randomized (significance lexel = 10%. power = 90%c).
Randomization of 400 patients would allow us to exclude a differ-
ence of 10%c with the same significance lexel and power. It was
decided to aim for 200 patients in the first instance and. if adequate
accrual was attained. the trial would continue to enter 400 patients.
Treatments
All patients w'ere planned to receive six cxcles of either MV or
CMV. Patients 'Aere re-exaluated after txo treatment cycles: if
treatment-related symptoms were stable. or improxed and simple
re-evaluation (physical examination. lixer function tests. chest
radiography and abdominal and/or pelvic ultrasound) showed no
evidence of disease progression. treatment was continued. in the
absence of disease progression. for six cycles.
Both regimens. MV and CMV. were gix en over a 21-day cycle.
MV compn'sed methotrexate at 30 mg m- given by slowx intra-
xvenous push on days 1 and 8 and vinblastine at 4 mc m-' gixenby
intraxenous push on days 1 and 8. Folinic acid rescue wxas gixen
24 h after each methotrexate injection at a dose of 15 mg orally. 6-
hourly x 4. CMV comprised MV gixven exactly as described. but
included, in addition. inpatient administration ofcisplatin at a dose
of 70 mg m- on day 2. Cisplatin was given following a period of
i.x. hvdration in which at least 2 1 of normal saline was ixven. and
'-as not administered until urine output Aas measured as equalling
or exceeding 100 ml h-I for 4 h. Cisplatin A-as administered in
500 ml of normal saline over 1 h and was followed bv at least ' 1
further hydration with normal saline. with supplementary potas-
sium chloride and magnesium sulphate.
All three chemotherapy drugs were gixen at full dose. on time. if
the white blood count was > 3.5 x 109 1-1 with a platelet count of
> l0Ox 10x1-1 and calculated GFR was >S0ml min-'. Metho-
trexate and xinblastine doses wAere reduced bx 25%7c for WBC 3-
3.5 x 109 1-1 and bv 50% for WBC 2.5-2.9 x 10' 1-1. A WBC of
<2.5 x 109 1-1 or platelets < 100 x 104 1-' on day 1 caused delay of
chemotherapy by up to 2 weeks: on day 8. chemotherapy was
omitted if these counts were found. A GFR of 35-50 ml on day 2
resulted in a reduction of cisplatin dose by 50%'c. Methotrexate and
cisplatin wAere omitted if the GFR Awas <35 ml mnn.-I
Investigations before and during treatment
Before entry into the study. a full physical examination Aas
performed and the WHO performance status recorded. A full
blood count and biochemical profile (including lixer function
tests. electroly-tes and urea and creatinine) Aere performed
together with chest radiography. CT scans of the chest. abdomen
and pelvis were obtained as clinicallx- indicated. Bone scanning,
Awas not mandatorv. but rather directed by symptoms.
Before each course of chemotherapy on days 1 and 8. a full
blood count and serum creatinine were obtained. At the end of
chemotherapy. formal re-exvaluation 'as performed. repeatinga all
initially abnormal investigations (except bone scanrnng) found at
the initiation of treatment.
End points and analysis
The date offirst progression ofcancer-related symptoms. first date
of objective disease progression (found on physical examination
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or radiolouicallv) and oxerall sur ixal were measured from the
date of randomization. Survival and progression-free sunrival
cunres were formed by the Kaplan-Meier method and compared
using the Mantel-Cox xversion of the log-rank test. To assess
whether CMV or MV wxere more or less effective in well-defined
subgroups. a X' test for heterogeneity or. when appropriate. trend
wxas performed. All analyses were performed on an intention-to-
treat basis. all tests are from a X' distribution with one degree of
freedom and all P-xvalues are two-sided unless otherwise specified
(Parmar and Machin. 1995). The statistical methods used were
implemented using SAS (1989).
Absolute benefits at specific time points for CMV for overall
survival were calculated using the Kaplan-Meier estimate for
survival on the MV arm at that time point (baseline sunrival).
using the expression: absolute benefit = exp (hazard ratio x log
baseline) - baseline sun-ixal. This approach wxas also adopted for
the end points of objective and symptomatic progression-free
survival. Although this approach implicitly assumes proportional
hazards. it is preferable to reading off differences between the
Kaplan-Meier curnes at indixidual time points (Parmar and
Machin. 1995).
Where possible. tumour response was recorded as the best
response achiexed duringa chemotherapy. Bone disease was
regyarded as non-exaluable. Complete remission required total
disappearance of disease both on physical examination and radio-
logically. Partial remission w-as defined as a reduction of at least
50% in the sum of the product of the cross-sectional diameters of
all measurable lesions. without progression at any site. Progressive
disease was defined as a > 25% increase recorded in the size ofanx
lesion. If patients did not satisfy anv of these criteria. theyxwere
defined as haxina stable disease.
Analvsis of prognostic factors was done by using, the Cox
proportional hazards model. To build a model. unixariate analyses
were done usinc a P- alue of0.10 to determine whether to include
a variable in the overall model. A forward selection procedure was
used to build a model and a prognostic index wxas developed. The
methods used in this whole process are described in Parmar and
Machin (1995).
RESULTS
From April 1991 to June 1995. 214 patients were entered into this
multi-institution study from a total of 16 centres within the UK.
Entrv bx institution is showxn in Table 1 and patient characteristics
are shown in Table 2. The patients were well matched with regard
to these patient characteristics in the two treatment groups.
Treatment delivery and response
One hundred and eight patients were randomized to receive combi-
nation chemotherapy with CMV and 106 patients were randomized
to receixe MV chemotherapy (Table 3). Forty patients (37%c)
completed a total of six cycles of CMV treatment - the median
numberofcycles received was four. Twenty-two patients (21%7c) allo-
cated MV completed six cycles oftreatment and the median number
ofcycles received was three. One patient in the MV arm changed his
mind afterrandomization and opted forCMV chemotherapy.
Disease progression occurred during, chemotherapy in 34
patients (32%7) receiving CMV and 72 patients (689%) receiving
MV. Clinical response was not a primary end point of this study.
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Figure 2 Kaplan-Meter curves of symptomatic progression-free survival in
the two treatment groups
Howex-er. of 88 patients allocated CMV wxith exaluable disease. a
complete response (CR) occurred in 10%c with a partial response
(PR) in 36% (CR + PR =46%7). Amonc 93 exaluable patients allo-
cated MV. a complete response occurred in 7%x with a partial
response in 12%c (CR + PR = 19%7).
Objective progression-free survival
A total of 208 patients have objectixely progressed or died. 104
allocated CMV and 104 allocated MV. A comparison of the
Kaplan-Meier curves (Figure 1) for the two treatments gives a
hazard ratio of0.55 (P-value = 0.0001: 95% confidence interval =
0.41-0.73). indicating a 45% reduction in the relatixe risk of
progression or death with CMV when compared with MV. This
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Table 1 Number of patients entered by each centre
Centre Total
Airedale General Hospital 4
Beatson Oncology Centre/BeMdere Hospital. Glasgow 39
Bristol Oncology Centre 11
Cheltenham General 3
Christie Hospital, Manchester 17
City/Queen Elizabeth Hospal. Birmingham 9
Clatterbridge Centre for Oncology 21
Cookridge Hospital, Leeds 2
Guys Hospital. London 18
Middlesex Hospital, London 20
Newcastle General/Freeman Hospital, Newcastle 22
Royal Free Hospital, London 1
Royal South Hants/St Marys Hospital. Southamptom 28
Velindre Hospital. Cardiff 3
Westmoiiand General Hospital/Royal Lancaster Infirmary 8
Weston Park Hospital. Sheffield 8
Total 214
translates to an improvement in median objectiVe progression-free
sunrival of 2.5 months (from 3 months to 5.5 months).
Symptomatic progression-free survival
A total of 209 patients have experienced symptomatic progression
or died. 104 allocated CMV and 105 allocated MV. The
Kaplan-Meier curves for the two treatments are shown in Firure
2. Comparing these two curves gives a hazard ratio of 0.48
(P-value = 0.0001: 95% confidence interval = 0.36-0.64). indi-
cating a 52% reduction in the relative risk ofsymptomatic progres-
sion or death w-ith CMV. This translates to a 2.5 month
improvement in median symptomatic progression-free surnsival
(from 2 months to 4.5 months).
Overall survival
A total of 204 patients haxe died. 101 allocated CMV and 103 allo-
cated MV. A comparison of the Kaplan-Meier curves (Figure 3)
rives a hazard ratio of 0.68 (P-value = 0.0065: 95% confidence
interval =0.51-0.90). indicatingy a 32% reduction in the relative risk
of death with CMV. This translates to a 2.5-month improvement in
median survival (from 4.5 months to 7 months) and an absolute
improvement of 13% in 1-year survival (from 16% to 29%).
At the time of analysis. seven patients allocated CMV remain
alive. four with disease and three without. The three patients
sithout disease had no further treatment. Two ofthe patients wvith
disease had further treatment - one cystectomy and one MVAC.
Of those allocated MV. three patients remam alive. one with
disease and two without. Of the two patients without disease. both
have had further treatment: one has had radiotherapy and
chemotherapy and the other has had a cystectomy. The one patient
alive with disease has had no further treatment for bladder cancer
but has had treatment for prostate cancer.
Toxicity
CMV treatment sas associated with considerablv more toxicitv
than MV. A total of five treatment-related deaths occurred in
patients receiving CMV (4c7c) and none in patients receiving MV.
Table 2 Patient characteristics
Treatment alocated
Total
CMV (%) MV (%) (%)
Age (years)
< 65 60 (56) 66 (62) 126 (59)
> 65 48 (44) 40 (38) 88 (41)
Median 65 64 64
Sex
Male 83 (77) 83 (78) 166 (78)
Female 25 (23) 23 (22) 48 (22)
WHO performance status
0 30 (28) 25 (23) 55 (26)
1 51 (47) 53 (50) 104 (48)
2 21 (19) 20(19) 41 (19)
3 6 (6) 8 (8) 14 (7)
Time since presentation (months)
0-5 60 (55) 46 (44) 106 (49)
6-12 18 (17) 29 (27) 47 (22)
>12 30 (28) 31 (29) 61 (29)
Site of primary tumour
Bladder 96 (89) 95 (90) 191 (89)
Other(kidney, prostate, ureter) 12(11) 11 (10) 23(11)
Previous treatment
None 31 (29) 24 (23) 55 (26)
Surgery 31 (29) 22 (21) 53 (25)
Radiotherapy + surgery 46 (42) 60 (56) 106 (49)
Extent of disease
Vsceral (bone, liver, lung. other) 61 (56) 56 (53) 117 (55)
Nodal (peMvts/abdominal) 39 (36) 37 (35) 76 (35)
Bladderrelapse 4 (4) 7 (7) 11 (5)
T4bat presentation 4 (4) 6 (6) 10 (5)
Total 108 (100) 106 (100) 214 (100)
Table 3 Summary of treatment
Treatment allocated
Total
CMV (%) MV (%) (%)
Treatment compieted (six cycles) 40 (37) 22 (21) 62 (29)
Disease progresskore 34 (32) 72 (68) 106 (50)
Toxicdeath during treatment 5 (4) 0 5 (3)
Excessive toxicity - treatnent stopped 16 (15) 0 16 (7)
lntercurrentdeath (due to neithertoxcity 2 (2) 2 (2) 4 (2)
nor progression)
Other medical condition - treatment stoppedt 5 (4) 4 (4) 9 (4)
Treatment stopped by clinican because no 3 (3) 5 (4) 8 (3)
improvement observed
Treatnentrefusal 3(3) 1 (1) 4(2)
Total 108 (100) 106 (100) 214 (100)
aSixpatients (three CMV. three MV) progressed before starting
chemotherapy and received nochemotherapy at all. t1 patient on CMV did
not start chemotherapy because of cardiac problems.
The cause ofdeath in these cases was cardiovascular toxicity(two
patients). septicaemia (two patients) and renal failure (one
patient). A further 16 patients (15%7c) receiving CMV were unable
to complete this treatment because of excessive toxicity.and three
more patients (3%7) refused to continue this treatment. whereas. in
patients receiving MV. no excessive toxicit problems Aere
British Joumal ofCancer(1998) 78(8), 1067-1075 0 Cancer Research Campaign 1998MV vs CMV in metastatic transitional cell cancer 1071
.z
co
1.0 1k
0.9
0.8
07-
0.7 -
051
0.4
0.3-
0.2
0.1 -
Events Total
101 108 CMV
103 106--- MV
u0u
0 3 6 9 12 15 18 21 24
Patients at nsk
CMV 108
MV 106
88
70
Months from randomization
63 47 35 21 14
46 31 17 8 6
8 7
5 5
Figure 3 Kaplan-Meier curves of overall survival in the two treatment
groups
reported and only one patient refused to continue treatment. CMV
resulted in grade Im leucopenia or thrombocytopenia in five cases
vs no cases with MV. Neutropenic fever requiring hospital admis-
sion and intravenous antibiotics was recorded in 11 patients
receiving CMV and two receiving MV. Grade I or H renal toxicity
occurred in. respectively. 19 cases and four patients receiving
CMV and MV.
Long-term toxicitv (neurological) was reported in nine CMV
patients and one patient on MV (although this patient actually
received CMV).
Effects in different subgroups
Table 4 shows the comparative effect ofCMV and MV in different
subgroups. for the main end point ofoverall survival. For each. the
X' test for interaction is presented. or where appropriate the X' test
for trend. There is some evidence of a larger effect in poor perfor-
mance status patients as opposed to good-performance patients
(Figure 4). There was no good evidence that the overall improved
survival effect observed with CMV was larger or smaller in any of
the other subgroups investigated.
Prognostic factors
The seven characteristics (factors) of patients collected before
randomnization and treatment (and presented in Table 2) were
analysed to assess whether they provided information which may
help to predict the prognosis of patients. Initially. all the factors
were analysed individually. The results of this analysis are
presented in Table 5. Only two factors. WHO performance status
and extent ofdisease. provide any good evidence of a relationship
with overall survival. Kaplan-Meier survival curves for the three
WHO performance status groups and the extent of disease groups
are shown in Figures 5 and 6. For extent of disease. the groups of
patients with nodal and bladder relapse/T4b disease had a similar
prognosis and. thus. were combined. In further analyses. therefore.
extent ofdisease was defined as visceral or non-visceral.
As WHO performance status was the factor with most evidence
of a relationship with overall survival. the other six characteristics
were added in turn to see if they contributed further information
above and beyond this factor. The only one for which there was
good evidence of adding information was extent of disease (chi-
square for inclusion = 14.575 on 1 degree of freedom. P-value =
0.0001). In the next step. the remaining five factors were added to
the model containing WHO performance status and extent of
disease. There was no evidence for any of the five remaining
factors adding further information.
Thus. from the seven factors considered. we conclude that only
WHO performance status (0. 1. 2/3) and extent of disease
(visceral. non-visceral) give useful independent information on the
likely survival ofpatients. Table 6 shows the final Cox model with
the estimates ofthe regression coefficients. To simplify the model.
we attempted to develop a prognostic index. The prognostic index
(PI) is used to derive a score from the key patient characteristics of
WHO and extent of disease. which can then be used to indicate
whether a patient has a good. intermediate or poor prognosis.
To derive a PI. it is usual to simplify the regression coefficients
in the fitted Cox model. The exponent part ofthe fitted Cox model
is 0.411W + 0.545E: preserving the ratio of the coefficients.
0.411:0.545 can be simplified to 3:4. giving PI = 3W + 4E (hence
the index scores in Table 6).
The PI can be calculated for each patient. which gives a range
from 0 to 10. a high score ofPI indicating a poorer prognosis and a
low score a better prognosis. The distribution of PI was examined
and convenient subgroups ofprognosis were identified. The good-
prognosis group were defined as having a PI < 4: this group of
patients includes those with WHO 0 or 1 and non-visceral disease.
Table 4 Effects in different subgroups
Subgroup Categories Ch lquare Degrees P-value
value from test of of
inlteacboieend freedom
Age se5. > 65 0.342 1 0.559
Sex Male, female 0.049 1 0.825
WHO performance status 0, 1, 213 5.395 1 0.020
Tlme since presentation (months) 0-5, 6-12, > 12 0.351 1 0.554
Site of tumour Bladder, kddney/prostate/ureter 2.003 1 0.157
Previous treatment None, surgery, radiotherapy ± surgery 1.409 2 0.494
Extent of disease Visceral, nodal, bladder relapse/T4b 1.204 2 0.548
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Table 5 Resufts of analysis of the relationship between pretreatment charactenstics (factors) and survival
Pretreatment characteristics Chi-sae Degrees of P-value
value freedom
Age
As a continuous variable 0.813 1 0.367
As a categoncal variable (S65, > 65) 0.360 1 0.549
Sex
(male, female) 0.317 1 0.573
WHO performance status
(0,1, 2/3) 17.244 1 0.00003
Time since presentaton (months)
As a continuous variable 0.024 1 0.877
As an ordered categorical variable (0-5, 6-12, > 12) 0.232 1 0.630
Previous treatment
(none, surgery, radiotherapy ± surgery) 0.095 2 0.954
Extent of disease
(visceral, nodal, bladder relapse/T4b) 16.486 2 0.0003
(visceral/non-visceral) 16.463 1 0.00005
Table 6 Prognostic factors and prognostc index scores
Prognostc factor Category Category Estimated SE HR Index score
score coelfI en=
WHO (W) 0 0 0 - 1 0
1 1 0.411 0.105 1.508 3
2/3 2 0.822 - 2.274 6
Extent of disease (E) Non-visceral 0 0 - 1 0
Visceral 1 0.545 0.144 1.725 4
(no. events/no. entered)
CMV MV O-E Variance
WHOO 28/30 22/25 0.30 12.23
WHO 1 48/51 53/53 -11.67 22.79
WHO 2/3 25/27 28/28 -10.30 10.99
0.0 0.5
CMV better
1.5 2.0
MV better
Figure 4 Hazard ratio plot of overall survival by WHO performance status
The intermediate-prognosis group had a PI of 4-6: this group
includes those with either a WHO 213 and no visceral disease or
WHO 0 and visceral disease. The poor-prognosis group had a PI >
6: this group includes those with WHO > 0 and visceral disease.
Table 7 shows the number ofpatients in each of these groups with
their median survival and -year survival rate. The survival curves
for each ofthese risk groups are shown in Figure 7.
DISCUSSION
Transitional cell carcinomas occur in a relatively elderly popula-
tion in whom coexisting medical illnesses are common. In prac-
tice. chemotherapy is difficult to give to these patients - both
because of the toxicity of the drugs at present in use and also
because of the commonly poor performance status of these
patients. A particular problem is impaired renal function. often
caused by obstructive uropathy. which may preclude therapy with
cisplatin and methotrexate. Many patients are not sufficiently fit to
receive treatment with chemotherapy for this disease. Among
those that are treated. it has become increasingly clear that treat-
ment is palliative for aHl except a small subgroup. In particular.
patients with visceral disease (particularly affecting the liver) are
rarely. if ever. cured. However. patients with nodal disease or
advanced pelvic disease at presentation (T4b). particularly those
with a good performance status. may be cured and thus may
warrant an intensive cisplatin-based treatment (Fossa et al. 1996).
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Table 7 Number of patients, median and 1-year survival according to
prognostic group
Prognostic Risk Number of Median survival One-year
index group pabents (%) (days) survival
< 4 Good 77 (36) 271 35°o
4-6 Medium 46 (21) 221 24o
> 6 Poor 94 (43) 112 15%o
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Figure 6 KaplanlMeier curves of overall survival by extent of disease
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Figure 5 Kaplan-Meier curves of overall survival by WHO performance
status
The results described in this. the second largest randoniized trial
reported in the literature. are infenror to those reported in both the
recent large randomized studies. i.e. the Intergroup trial comparing
cisplatin with M-VAC (Loehrer et al. 1994) and the MD Anderson
study of M-VAC vs CISCA (Logothetis et al. 1990). There are a
number ofpossible explanations for this. We deliberately chose to be
as inclusive as possible in our study to represent as nearly as possible
the true nature of this patient population. In this regard. we accepted
patients with a relatively low GFR (greater than 50 ml min-') and
used a lowerdose ofcisplatin than used in the original CMV regimen
(70 mg m-' vs 100 mg m-: Harker et al. 1986). although there is no
good evidence to suggest that this latter approach may be disadvanta-
geous. Approximatelv 50% of our patients had received previous
radiation compared with 25-30% in most series derived from the US.
We deliberately included patients with non-measurable disease. a
common situation following pelvic radiation which may be associ-
ated with an adverse outlook (Jeffery et al. 1992).
The study adequately highlighted the beneficial effect of
cisplatin. increasing the median surnival from 4.5 to 7.5 months
and the -year survival from 16%7 to 29%. Improvements were also
seen in symptomatic and objective progression-free sunival.
However. the toxicity of CMV and the relative inefficacy of both
these regimens was highlighted both by the low proportion of
patients completing the planned six cycles ofchemotherapy and by
the high proportion of patients discontinuing chemotherapy
because ofdisease progression or excessive toxicity.
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Figure 7 KaplanrMeier curves of overall survival for good-. medium- and
poor-risk groups
A study by Saxman et al ( 1997) found that the best pretreatment
predictors of survival in patients with metastatic urothelial carci-
noma included performance status. histology and the presence of
liver or bone metastases. In this study. using a population of
patients with transitional cell carcinoma only. we found perfor-
mance status and extent of disease to be the best predictors of
surnival. The extent of disease defined as xvisceral/non-visceral
corresponds largely to the liver and bone metastases variables used
by Saxman et al. We used the factors of performance status and
extent of disease to produce a prognostic index. which could be
used to classify patients into groups.
We. like other inxestigators (Tannock et al. 1989). conclude
from this study that the drugs incorporated in CMV (or M-VAC).
while achiex ing short-term disease regression. on the whole
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pro'ide poor palliation for a majority of patients. A number of
studies have attempted to increase the dose intensity ofM-VAC by
simultaneous administration of orowth factors (Loehrer et al.
1994: Logothetis et al. 1985). The majoritv of these studies have
concluded that this resulted in a modest increase in dose intensitv.
with markedlv increased toxicity with no obvious clinical benefits.
However. the European Organization for Research and Treatment
of Cancer. following a successful randomized phase II trial in
which no increase in toxicity was seen (Sternbera et al. 1997). is
currently randomizing patients in a phase III trial between M-VAC
and accelerated M-VAC supported by growth factors.
A number of new drugs and drug combinations are now under
early staaes of evaluation by ourselves and others. These agents
include the taxanes. paclitaxel (Roth et al. 1994) and docetaxel
(McCaffrey et al. 1995). g!emcitabine (Stadler et al. 1995) ifos-
famide (Witte et al. 1997) and gallium (Seligman et al. 1991).
Other drugs such as fluorouracil are being re-evaluated and the
MRC has commenced a phase H study of infusional fluorouracil.
New drug combinations are also in development. One drug combi-
nation recently evaluated - VIG (vinblastine. ifosfamide and
gallium) - was not recommended for further study. Other combi-
nations of the newer drugs are at present under evaluation and
randomized trial comparisons of these approaches are under way
or at the planning stage. The experience of this study. however.
does suagest that a word of caution is appropriate. It seems inher-
ently unlikelv that these new combinations will markedl1 increase
the proportion of patients who are long-term surviVors.
New prospective studies should therefore examine not only
response rates and survival. but also quality of life to assess the true
impact oftherapies. which are often toxic. on this patient population.
In summarv. this randomized trial demonstrated a clear
improvement in symptomatic and objective pro-ression-free
survival. together with survival as a result of the addition of
cisplatin to methotrexate and vinblastine. This improvement in
anti-cancer effect was. however. achieved at the cost of increased
toxicity. Cisplatin containing combinations can be recommended
for patients in whom benefit is likely to exceed toxicity. New- treat-
ment approaches should be supported and evaluated in random-
ized clinical tnials.
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